|
Aug 5
|
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
|
|
Aug 5
|
Genmab Takes Full Control of Acasunlimab Development Program
|
|
Jul 29
|
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Jun 28
|
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
|
|
Jun 27
|
Completion of Share Buy-back Program
|
|
Jun 27
|
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
|
|
Jun 26
|
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
|
|
Jun 17
|
Transactions in Connection with Share Buy-back Program
|
|
Apr 15
|
Roche reports survival data for new dual-acting lymphoma drug
|
|
Apr 15
|
Transactions in Connection with Share Buy-back Program Genmab
|
|
Feb 27
|
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
|
|
Feb 27
|
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
|
|
Feb 26
|
Transactions in connection with share buy-back program
|
|
Feb 23
|
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
|
|
Jan 9
|
GMAB or TECH: Which Is the Better Value Stock Right Now?
|
|
Jan 9
|
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 9
|
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
|
|
Jan 2
|
Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 9
|
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
|